Leukocytoclastic Vasculitis Associated with Bortezomib Therapy

0Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

A 28-year-old male, 10 years post live-related renal transplant with stable graft function of 1.4 mg/dL, presented with complaints of loss of appetite and vomiting for three days. On evaluation, he was found to have significant graft dysfunction with a creatinine of 10.3 mg/dL. He was initiated on hemodialysis in view of uremic gastrointestinal symptoms. Graft biopsy done revealed acute cell-mediated rejection BANFF IIB and diffuse C4d-positive antibody-mediated rejection. He was treated with intravenous methylprednisolone, therapeutic plasma exchange, and intravenous immunoglobulin therapy, following which his graft function improved gradually. He received multiple injections of bortezomib as a part of anti-rejection treatment protocol and developed peripheral neuropathy, leukocytoclastic vasculitis, and varicellosis. This case report is to highlight the unusual phenomenon of leukocytoclastic vasculitis in a post renal transplant setting secondary to bortezomib therapy.

Cite

CITATION STYLE

APA

Yashwanth, T., Vairakkani, R., Srinivasaprasad, N., Sujith, S., Thirumalvalavan, K., & Fernando, M. (2020). Leukocytoclastic Vasculitis Associated with Bortezomib Therapy. Saudi Journal of Kidney Diseases and Transplantation, 31(5), 1106–1109. https://doi.org/10.4103/1319-2442.301178

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free